106 STAT. 4504 PUBLIC LAW 102-571—OCT. 29, 1992 M: and Commerce of the House of Representatives and the Committee on Labor and Human Resources of the Senate a final report containing the findings resulting from the study and the recommendations described in subparagraph (B). (B) RECOMMENDATIONS. — Such report shall contain the recommendations described in paragraph (I)(B). SEC. 206. SAFETY AND REGULATORY OUTCOMES STUDY. (a) SAFETY STUDY.—The Director of the Office of Technology Assessment, in cooperation with the Congressional Research Service and subject to the approval of the Technology Assessment Board, shall conduct a study of the relationship between— (1) regulatory systems affecting the development and sale of dietary supplements of vitamins, minerals, herbs, or other similar nutritional substances; and (2) health outcomes. (b) CONTENTS. — (1) IN GENERAL.—In carrying out the study, the Director of the Office of Technology Assessment shall examine the efforts of industrialized nations (including the United States) to regulate the manufacture and sale of such dietary supplements and the effect of the regulatory efforts on human health. (2) INFORMATION. —The study shall include information regarding— (A) whether and how other countries regulate products that are regulated as such dietary supplements in the United States; (B) the classification systems used in regulating such products, such as systems that classify such supplements by safety, function, source, usage, dose, or other characteristics; (C) the effect of the classification on the regulation of the supplements; (D) now safety concerns, including safety concerns at the time of manufacture and sale of the product are addressed by the regulatory process; (E) how deception concerns (including misbranding) are addressed by the regulatory process; and (F) the labeling requirements, if any, for the sale of the products. (3) ANALYSIS.—The study shall also examine— (A) whether there are disparate rates of morbidity and mortality associated with the consimiption of such dietary supplements among nations; (B) whether particular regulatory systems may be associated with lower morbidity and mortality rates; and (C) whether a causal relationship may be demonstrated between the regulatory system used and the health outcomes of the populations affected.
�
